Is human immunodeficiency virus-mediated dementia an autophagic defect that leads to neurodegeneration?

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 9, 2014, Pages 1571-1579

  Passeri, Eleonora ^a   Mocchetti, Italo ^a   Moussa, Charbel ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Autophagy; Beclin 1; Gp120; Lysosomes; Parkin

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANTIRETROVIRUS AGENT; BECLIN 1; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; IMATINIB; LIGHT CHAIN PROTEIN 3; LIGHT CHAIN PROTEIN 3 I; LIGHT CHAIN PROTEIN 3 II; LIGHT CHAIN PROTEIN 3 III; MAMMALIAN TARGET OF RAPAMYCIN; MICROTUBULE ASSOCIATED PROTEIN 1; NILOTINIB; PARKIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BRAIN ATROPHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOCYTOSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYSOSOME; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; VIRUS ENCEPHALITIS;

EID: 84920578554     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140806125841     Document Type: Article

References (122)

1. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol 2013; 13:722-37.
2. Gutierrez MG, Master SS, Singh SB, et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119: 753-66.
3. Nakagawa I, Amano A, Mizushima N, et al. Autophagy defends cells against invading group A Streptococcus. Science 2004; 306:1037-40.
4. Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544.
5. Seglen PO. Regulation of autophagic protein degradation in isolated liver cells. In: Lysosomes: Their Role in Protein Breakdown: edn. Glaumann H, Ballard FJ, Eds. London: Academic Press 1987: pp. 369-414.
6. de Duve C, Wattiaux R. Functions of lysosomes. Annu Rev Physiol 1966; 28:435-92.
7. Dunn WA, Jr. Autophagy and related mechanisms of lysosomemediated protein degradation. Trends Cell Biol 1994; 4:139-43.
8. Gordon PB, Seglen PO. Prelysosomal convergence of autophagic and endocytic pathways. Biochem Biophys Res Commun 1988; 151:40-7.
9. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009; 43 67-93.
10. Jahreiss L, Menzies FM, Rubinsztein DC. The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. Traffic 2008; 9:574-87.
11. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 2010; 22:132-9.
12. Chan EY, Longatti A, McKnight NC, Tooze SA. Kinaseinactivated ULK proteins inhibit autophagy via their conserved Cterminal domains using an Atg13-independent mechanism. Mol Cell Biol 2009; 29:157-71.
13. Shang L, Wang X. AMPK and mTOR coordinate the regulation of Ulk1 and mammalian autophagy initiation. Autophagy 2011; 7:924-6.
14. Rubinsztein DC, Shpilka T, Elazar Z. Mechanisms of autophagosome biogenesis. Curr Biol 2012; 22:R29-34.
15. Ohsumi Y, Mizushima N. Two ubiquitin-like conjugation systems essential for autophagy. Semin Cell Dev Biol 2004; 15:231-6.
16. Hochstrasser M. Origin and function of ubiquitin-like proteins. Nature 2009; 458:422-9.
17. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3: 542-5.
18. Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544.
19. Di Bartolomeo S, Corazzari M, Nazio F, et al. The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy. J Cell Biol 2010; 191:155-68.
20. Fimia GM, Stoykova A, Romagnoli A, et al. Ambra1 regulates autophagy and development of the nervous system. Nature 2007; 447:1121-5.
21. Pattingre S, Tassa A, Qu X, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122:927-39.
22. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40:280-93.
23. Stoica L, Zhu PJ, Huang W, et al. Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc Natl Acad Sci USA 2011; 108:3791-6.
24. Jossin Y, Goffinet AM. Reelin signals through phosphatidylinositol 3-kinase and Akt to control cortical development and through mTor to regulate dendritic growth. Mol Cell Biol 2007; 27:7113-24.
25. Wong ES, Tan JM, Soong WE, et al. Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum Mol Genet 2008; 17:2570-82.
26. Ulamek-Koziol M, Furmaga-Jablonska W, Januszewski S, et al. Neuronal autophagy: self-eating or self-cannibalism in Alzheimer's disease. Neurochem Res 2013; 38:1769-73.
27. Keilani S, Lun Y, Stevens AC, et al. Lysosomal dysfunction in a mouse model of Sandhoff disease leads to accumulation of ganglioside-bound amyloid-beta peptide. J Neurosci 2012; 32:5223-36.
28. Jaeger PA, Pickford F, Sun CH, et al. Regulation of amyloid precursor protein processing by the Beclin 1 complex. PLoS One 2010; 5:e11102.
29. Illi B, Dello Russo C, Colussi C, et al. Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. Circ Res 2008; 102:51-8.
30. Martin M, Potente M, Janssens V, et al. Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis. Proc Natl Acad Sci USA 2008; 105:4727-32.
31. Simboeck E, Sawicka A, Zupkovitz G, et al. A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors. J Biol Chem 2010; 285(52):41062-73.
32. Vingtdeux V, Chandakkar P, Zhao H, et al. Novel synthetic smallmolecule activators of AMPK as enhancers of autophagy and amyloid-{beta} peptide degradation. FASEB J 2011; 25(1):219-31.
33. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem 2010; 285:13107-20.
34. Khandelwal PJ, Herman AM, Hoe HS, Rebeck GW, Moussa CE. Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models. Hum Mol Genet 2011; 20:2091-102.
35. Herman AM, Moussa CE. The ubiquitin ligase parkin modulates the execution of autophagy. Autophagy 2011; 7:919-21.
36. Pickford F, Masliah E, Britschgi M, et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 2008; 118:2190-9.
37. Lonskaya I, Hebron ML, Desforges NM, Franjie A, Moussa CE. Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance. EMBO Mol Med 2013; 5:1247-62.
38. Yang DS, Stavrides P, Mohan PS, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 2011; 134:258-77.
39. Dehay B, Bove J, Rodriguez-Muela N, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010; 30:12535-44.
40. Nixon RA, Wegiel J, Kumar A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 2005; 64:113-22.
41. Pan T, Kondo S, Le W, Jankovic J. The role of autophagylysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008; 131:1969-78.
42. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36:585-95.
43. Sarkar S, Perlstein EO, Imarisio S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol 2007; 3:331-8.
44. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperonemediated autophagy. Science 2004; 305:1292-5.
45. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopaminemodified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008; 118:777-88.
46. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 2009; 4:e5515.
47. Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008; 60:748-66.
48. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392:605-8.
49. Lucking CB, Durr A, Bonifati V, et al. Association between earlyonset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342:1560-7.
50. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25:302-5.
51. Lonskaya I, Shekoyan AR, Hebron ML, et al. Diminished parkin solubility and co-localization with intraneuronal amyloid-beta are associated with autophagic defects in Alzheimer's disease. J Alzheimers Dis 2013; 33:231-47.
52. Lonskaya I, Hebron ML, Algarzae NK, Desforges N, Moussa CE. Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease. Neuroscience 2012; 232C:90.
53. Geisler S, Holmstrom KM, Skujat D, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 2010; 12:119-31.
54. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183:795-803.
55. Park J, Kim Y, Chung J. Mitochondrial dysfunction and Parkinson's disease genes: insights from Drosophila. Dis Model Mech 2009; 2:336-40.
56. Vives-Bauza C, Zhou C, Huang Y, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci USA 2010; 107:378-83.
57. Thomas KJ, McCoy MK, Blackinton J, et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet 2011; 20(1): 40-50.
58. Moussa CE. Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein. J Mol Neurosci 2009; 37:25-36.
59. Rodriguez-Navarro JA, Rodriguez L, Casarejos MJ, et al. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol Dis 2010; 39:423-38.
60. Chen D, Gao F, Li B, et al. Parkin Mono-ubiquitinates Bcl-2 and Regulates Autophagy. J Biol Chem 2010; 285:38214-23.
61. Hebron ML, Lonskaya I, Moussa CE. Tyrosine kinase inhibition facilitates autophagic SNCA/alpha-synuclein clearance. Autophagy 2013; 9:1249-50.
62. Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum Mol Genet 2013; 22:3315-28.
63. Deretic V, Levine B. Autophagy, immunity, and microbial adaptations. Cell Host Microbe 2009; 5:527-49.
64. Tucker KA, Reggiori F, Dunn WA Jr, Klionsky DJ. Atg23 is essential for the cytoplasm to vacuole targeting pathway and efficient autophagy but not pexophagy. J Biol Chem 2003; 278:48445-52.
65. Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008; 319:921-6.
66. Kyei GB, Dinkins C, Davis AS, et al. Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages. J Cell Biol 2009; 186:255-68.
67. Gannage M, Dormann D, Albrecht R, et al. Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe 2009; 6:367-80.
68. Perumal MB, Dhanasekaran S. HIV associated dementia: role for neurosteroids. Med Hypotheses 2012; 78:672-4.
69. Dahiya S, Irish BP, Nonnemacher MR, Wigdahl B. Genetic variation and HIV-associated neurologic disease. Adv Virus Res 2013; 87:183-240.
70. Dal Pan GJ, McArthur JH, Aylward E, et al. Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis. Neurology 1992; 42:2125-30.
71. Spudich S, Gonzalez-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med 2012; 2: a007120.
72. Everall I, Vaida F, Khanlou N, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 2009; 15:360-70.
73. Soudeyns H, Rebai N, Pantaleo GP, et al. The T cell receptor V beta repertoire in HIV-1 infection and disease. Semin Immunol 1993; 5:175-85.
74. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997; 385:645-9.
75. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990; 250:1139-42.
76. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73.
77. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV- 1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.
78. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85:1149-58.
79. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5.
80. Jordan CA, Watkins BA, Kufta C, Dubois-Dalcq M. Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent. J Virol 1991; 65:736-42.
81. Albright AV, Shieh JT, Itoh T, et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol 1999; 73:205-13.
82. Eugenin EA, Clements JE, Zink MC, Berman JW. Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. J Neurosci 2011; 31:9456-65.
83. Bachis A, Biggio F, Major EO, Mocchetti I. M- and T-tropic HIVs promote apoptosis in rat neurons. J Neuroimmune Pharmacol 2009; 4:150-60.
84. Dheen ST, Kaur C, Ling EA. Microglial activation and its implications in the brain diseases. Curr Med Chem 2007; 14:1189-97.
85. Bertrand SJ, Aksenova MV, Mactutus CF, Booze RM. HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. Exp Neurol 2013; 248:228-35.
86. Hui L, Chen X, Haughey NJ, Geiger JD. Role of endolysosomes in HIV-1 Tat-induced neurotoxicity. ASN Neurol 2012; 4:243-52.
87. Bezzi P, Domercq M, Brambilla L, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001; 4:702-10.
88. Bansal AK, Mactutus CF, Nath A, et al. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res 2000; 879:42-9.
89. van Marle G, Henry S, Todoruk T, et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology 2004; 329:302-18.
90. Meucci O, Miller RJ. gp120-induced neurotoxicity in hippocampal pyramidal neuron cultures: protective action of TGF-beta1. J Neurosci 1996; 16:4080-8.
91. Hesselgesser J, Taub D, Baskar P, et al. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol 1998; 8:595-8.
92. Toggas SM, Masliah E, Rockenstein EM, et al. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994; 367:188-93.
93. Bachis A, Avdoshina V, Zecca L, Parsadanian M, Mocchetti I. Human immunodeficiency virus type 1 alters brain-derived neurotrophic factor processing in neurons. J Neurosci 2012; 32:9477-84.
94. Famularo G, De Simone C, Marcellini S. Apoptosis: mechanisms and relation to AIDS. Med Hypotheses 1997; 48:423-9.
95. Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999; 96:8212-6.
96. Meucci O, Fatatis A, Simen AA, et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA 1998; 95:14500-5.
97. Kuan CY, Roth KA, Flavell RA, Rakic P. Mechanisms of programmed cell death in the developing brain. Trends Neurosci 2000; 23:291-7.
98. Haughey NJ, Cutler RG, Tamara A, et al. Perturbation of sphingolipid metabolism and ceramide production in HIVdementia. Ann Neurol 2004; 55:257-67.
99. Bodner A, Toth PT, Miller RJ. Activation of c-Jun N-terminal kinase mediates gp120IIIB- and nucleoside analogue-induced sensory neuron toxicity. Exp Neurol 2004; 188:246-53.
100. Volosin M, Song W, Almeida RD, et al. Interaction of survival and death signaling in basal forebrain neurons: roles of neurotrophins and proneurotrophins. J Neurosci 2006; 26: 7756-66.
101. Mocchetti I, Bachis A. Brain-derived neurotrophic factor activation of TrkB protects neurons from HIV-1/gp120-induced cell death. Crit Rev Neurobiol 2004; 16:51-7.
102. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003; 422:37-44.
103. Bachis A, Aden SA, Nosheny RL, Andrews PM, Mocchetti I. Axonal transport of human immunodeficiency virus type 1 envelope protein glycoprotein 120 is found in association with neuronal apoptosis. J Neurosci 2006; 26:6771-80.
104. Melli G, Keswani SC, Fischer A, Chen W, Hoke A. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy. Brain 2006; 129:1330-8.
105. Espert L, Denizot M, Grimaldi M, et al. Autophagy and CD4+ T lymphocyte destruction by HIV-1. Autophagy 2007; 3:32-4.
106. Fields J, Dumaop W, Rockenstein E, et al. Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer. J Neurovirol 2013; 19:89-101.
107. Wang Y, Dong XX, Cao Y, et al. p53 induction contributes to excitotoxic neuronal death in rat striatum through apoptotic and autophagic mechanisms. Eur J Neurosci 2009; 30: 2258-70.
108. Kragh CL, Ubhi K, Wyss-Coray T, Masliah E. Autophagy in dementias. Brain Pathol 2012; 22:99-109.
109. Kim PK, Hailey DW, Mullen RT, Lippincott-Schwartz J. Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc Nat Acad Sci USA 2008; 105: 20567-74.
110. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004; 15:1101-11.
111. Huang W-P, Scott SV, Kim J, Klionsky DJ. The itinerary of a vesicle component, Aut7p/Cvt5p, terminates in the yeast vacuole via the autophagy/Cvt pathways. J Biol Chem 2000; 275:5845-51.
112. Bultmann A, Eberle J, Haas J. Ubiquitination of the human immunodeficiency virus type 1 env glycoprotein. J Virol 2000; 74:5373-6.
113. Khandelwal PJ, Dumanis SB, Feng LR, et al. Parkinson-related parkin reduces alpha-Synuclein phosphorylation in a gene transfer model. Mol Neurodegener 2010; 5:47.
114. Mahul-Mellier A-L, Fauvet B, Gysbers A, et al. c-Abl phosphorylates α -synuclein and regulates its degradation: implication for α -synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet 2014; 23(11):2858-79.
115. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540-6.
116. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26:3358-63.
117. Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008; 30:1956-75.
118. Skorski T. BCR-ABL1 kinase: hunting an elusive target with new weapons. Chem Biol 2011; 18:1352-3.
119. Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008; 68:9809-16.
120. Keller VAG, Brummendorf TH. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther 2012; 12:1121-7.
121. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011; 118:4567-76.
122. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr- Abl+ neoplastic cells. Cancer Res 2006; 66:11314-22.